Business Context and Reporting Period
This Form 8-K is a current report filed by Frequency Therapeutics, Inc. (not Korro Bio, Inc.) on September 23, 2020. The registrant is a Delaware corporation with its principal executive offices in Woburn, MA, and its common stock trades on the Nasdaq Global Select Market under the symbol FREQ. The company is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and legal amendments rather than financial performance.
Material Changes
- Board Appointment: On September 23, 2020, the Board of Directors appointed Cynthia Feldmann as a Class II Director. She was also appointed to the Audit Committee.
- Compensation: Ms. Feldmann will receive compensation in accordance with the Company's standard arrangements for non-management directors. No special arrangement or understanding existed for her election.
- Bylaws Amendment: The Board approved an amendment to the Amended and Restated Bylaws to adopt a new Article XI (Forum Selection). This provision designates the federal district courts of the United States as the exclusive forum for complaints arising under the Securities Act, unless the Company consents in writing to an alternative forum.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future outlook, or specific risk factors beyond the legal implications of the new forum selection clause. The press release announcing the appointment is furnished as an exhibit but is not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the full text of the Amended and Restated Bylaws (Exhibit 3.1) to understand the scope of the new forum selection provision.
- Review the Press Release (Exhibit 99.1) for additional context on Cynthia Feldmann's background and qualifications.
- Confirm the company's status as an emerging growth company and any associated reporting exemptions.
- Note that this filing contains no financial data; refer to the most recent 10-Q or 10-K for financial metrics.